Elemer Piros
Stock Analyst at Rodman & Renshaw
(3.20)
# 1,070
Out of 4,784 analysts
110
Total ratings
36.54%
Success rate
4.14%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BTAI BioXcel Therapeutics | Initiates: Buy | $65 | $2.12 | +2,966.04% | 1 | Mar 19, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.95 | +1,163.16% | 1 | Dec 12, 2024 | |
| THAR Tharimmune | Initiates: Buy | $17 | $1.41 | +1,105.67% | 1 | Dec 6, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $1.35 | +714.81% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $40.33 | +23.98% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.06 | +1,503.77% | 1 | Sep 30, 2024 | |
| ATHA Athira Pharma | Initiates: Buy | $22 | $0.31 | +7,113.11% | 1 | Aug 19, 2024 | |
| SAVA Cassava Sciences | Reiterates: Buy | $107 | $1.65 | +6,384.85% | 1 | Aug 8, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $0.42 | +3,267.81% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $1.65 | +3,960.61% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $2.27 | +1,794.27% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $6.56 | +174.39% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $1.03 | +628.16% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $1.47 | +920.41% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $6.19 | +239.26% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $2.94 | +1,192.52% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $1.34 | +2,885.07% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.61 | +714.33% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $114 | $6.72 | +1,596.43% | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $3.22 | +6,111.18% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $3.41 | +574.49% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $11.06 | +198.37% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $24.27 | +64.81% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $40 | $1.14 | +3,408.77% | 3 | Jan 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.81 | +1,944.20% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $3.82 | +737.70% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $11.58 | +564.94% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $0.80 | +8,650.00% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.52 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $13.82 | +261.79% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $6.67 | +394.75% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $13.68 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $8.47 | +206.97% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $183.92 | -84.78% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $4.97 | +17,002.62% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $7.58 | +177.04% | 2 | Jul 12, 2017 |
BioXcel Therapeutics
Mar 19, 2025
Initiates: Buy
Price Target: $65
Current: $2.12
Upside: +2,966.04%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $0.95
Upside: +1,163.16%
Tharimmune
Dec 6, 2024
Initiates: Buy
Price Target: $17
Current: $1.41
Upside: +1,105.67%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $1.35
Upside: +714.81%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $40.33
Upside: +23.98%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.06
Upside: +1,503.77%
Athira Pharma
Aug 19, 2024
Initiates: Buy
Price Target: $22
Current: $0.31
Upside: +7,113.11%
Cassava Sciences
Aug 8, 2024
Reiterates: Buy
Price Target: $107
Current: $1.65
Upside: +6,384.85%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $0.42
Upside: +3,267.81%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $1.65
Upside: +3,960.61%
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $2.27
Upside: +1,794.27%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $6.56
Upside: +174.39%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $1.03
Upside: +628.16%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $1.47
Upside: +920.41%
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $6.19
Upside: +239.26%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $2.94
Upside: +1,192.52%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $1.34
Upside: +2,885.07%
Jun 30, 2023
Reiterates: Buy
Price Target: $5
Current: $0.61
Upside: +714.33%
Jun 20, 2023
Reiterates: Buy
Price Target: $114
Current: $6.72
Upside: +1,596.43%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $3.22
Upside: +6,111.18%
May 16, 2023
Reiterates: Buy
Price Target: $23
Current: $3.41
Upside: +574.49%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $11.06
Upside: +198.37%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $24.27
Upside: +64.81%
Jan 4, 2022
Upgrades: Buy
Price Target: $40
Current: $1.14
Upside: +3,408.77%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.81
Upside: +1,944.20%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $3.82
Upside: +737.70%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $11.58
Upside: +564.94%
Oct 12, 2020
Initiates: Buy
Price Target: $70
Current: $0.80
Upside: +8,650.00%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $5.52
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $13.82
Upside: +261.79%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $6.67
Upside: +394.75%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $13.68
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $8.47
Upside: +206.97%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $183.92
Upside: -84.78%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $4.97
Upside: +17,002.62%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $7.58
Upside: +177.04%